StreetInsider.com News Articles

Annovis to Host Corporate Update Webinar on September 2, 2026

Tue, 25 Aug 2026 08:00:00 -0400

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.

The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upcoming milestones.

Webinar details

Date: Wednesday, September 2, 2026
Time: 4:00 p.m. EDT
Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO
Registration link

Annovis to Host Corporate Update Webinar on September 2, 2026

Tue, 25 Aug 2026 08:00:00 -0400

The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upcoming milestones.

Webinar details

Date: Wednesday, September 2, 2026
Time: 4:00 p.m. EDT
Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO
Registration link

Annovis to Host Corporate Update Webinar on September 2, 2026

Tue, 25 Aug 2026 08:00:00 -0400

The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upcoming milestones.

Webinar details

Date: Wednesday, September 2, 2026
Time: 4:00 p.m. EDT
Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO
Registration link

Annovis to Host Corporate Update Webinar on September 2, 2026

Tue, 25 Aug 2026 08:00:00 -0400

The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upcoming milestones.

Webinar details

Date: Wednesday, September 2, 2026
Time: 4:00 p.m. EDT
Presenter: Maria Maccecchini, Ph.D., Founder, President, and CEO
Registration link

Form PRE 14A Annovis Bio, Inc. For: Aug 24

Tue, 25 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260825/26970315.html

Form PRE 14A Annovis Bio, Inc. For: Aug 24

Tue, 25 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260825/26970315.html

Canaccord Reiterates Buy Rating on Annovis Bio Inc. (ANVS)

Tue, 18 Aug 2026 07:00:03 -0400

Canaccord analyst Sumant Kulkami reiterated a Buy rating and $17.00 price target on Annovis Bio Inc. (NYSE: ANVS).

The analyst commented: "ANVS reported its 2Q26 results on 8/17. Operating expenses came in lower at $14.4mn vs. our $18.3mn. Lower R&D, potentially due to timing, which remains difficult to predict, drove the delta vs. our model. Recall, ANVS is developing buntanetap, which is in a Phase 3 trial for early Alzheimer's disease (AD) with 6-month (symptomatic) and 18-month (disease-progression) components. As the company also stated at our recent 46th Annual Growth Conference in Boston, MA (see here ), ANVS reiterated that it

Form 10-Q Annovis Bio, Inc. For: Jun 30

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931632.html

Form 10-Q Annovis Bio, Inc. For: Jun 30

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931632.html

Form 8-K Annovis Bio, Inc. For: Aug 14

Fri, 14 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26930316.html

Form 8-K Annovis Bio, Inc. For: Aug 14

Fri, 14 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26930316.html

Form SCHEDULE 13G Annovis Bio, Inc. Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC

Fri, 14 Aug 2026 12:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26927966.html

Form SCHEDULE 13G Annovis Bio, Inc. Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC

Fri, 14 Aug 2026 12:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26927966.html

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.
Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients with full enrollment projected in Q4 2026.
Annovis will host a corporate update webinar on Wednesday, September 2, 2026, at 4:00 pm EDT.

MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.
Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients with full enrollment projected in Q4 2026.
Annovis will host a corporate update webinar on Wednesday, September 2, 2026, at 4:00 pm EDT.

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.
Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients with full enrollment projected in Q4 2026.
Annovis will host a corporate update webinar on Wednesday, September 2, 2026, at 4:00 pm EDT.

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Fri, 14 Aug 2026 08:00:00 -0400

Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections.
Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients with full enrollment projected in Q4 2026.
Annovis will host a corporate update webinar on Wednesday, September 2, 2026, at 4:00 pm EDT.

Form SCHEDULE 13G Annovis Bio, Inc. Filed by: Empery Asset Management, LP

Wed, 29 Jul 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260729/26835329.html

Form SCHEDULE 13G Annovis Bio, Inc. Filed by: Empery Asset Management, LP

Wed, 29 Jul 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260729/26835329.html

Form 8-K Annovis Bio, Inc. For: Jul 07

Fri, 10 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260710/26754824.html

Form 8-K Annovis Bio, Inc. For: Jul 07

Fri, 10 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260710/26754824.html

Roth/MKM Starts Annovis Bio Inc. (ANVS) at Buy

Tue, 07 Jul 2026 16:12:41 -0400

Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on Annovis Bio Inc. (NYSE: ANVS) with a Buy rating.

For an analyst ratings summary and ratings history on Annovis Bio Inc. click here. For more ratings news on Annovis Bio Inc. click here.

Shares of Annovis Bio Inc. closed at $1.97 yesterday.

Annovis Bio completes enrollment of 850 patients in Phase 3 AD trial

Tue, 07 Jul 2026 07:00:25 -0400

Annovis Bio, Inc. (NYSE: ANVS) announced it has completed enrollment in its pivotal Phase 3 clinical trial evaluating buntanetap for early Alzheimer's disease, enrolling 850 patients across 83 clinical sites in the United States, exceeding the company's original enrollment target.

The trial, identified as NCT06709014, is a randomized, placebo-controlled, double-blind study enrolling patients diagnosed with early Alzheimer's disease, defined by a Mini-Mental State Examination score of 20 to 28 and confirmed positive for the blood biomarker pTau217. Participants receive a daily oral dose of 30mg buntanetap. Primary endpoints measure changes in cognition using the ADAS-Cog13 scale and function using the ADCS-iADL

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Tue, 07 Jul 2026 07:00:00 -0400

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections

Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028

Company positions for two NDA submissions following each readout

MALVERN, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced full enrollment of its pivotal Phase 3 trial (NCT06709014) evaluating

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Tue, 07 Jul 2026 07:00:00 -0400

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections

Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028

Company positions for two NDA submissions following each readout